ClinicalTrials.gg
Active, not recruitingNCT05929937Updated Mar 6, 2026

No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair

A Phase 4 interventional study of Opioids and No opioids in Postoperative Pain and Inguinal Hernia, sponsored by Clayton Petro. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Clayton Petro · Phase 4, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
904
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 329 studies testing opioids in Pain, Postoperative — 53 open to participants now, 65 under way, 6 of them phase 3. A drug class: Opioids · Pain, Postoperative.

Planned enrollment
6th of 329
904 · median 84
Started
2023
with 18 others
Phase 4
145 of 329
26 open now
Primary completion
2027-06
later than 43 of 64 live
Registered
246th of 329
by date

Among the 329 studies testing opioids in Pain, Postoperative, this one is the 6th largest by planned enrollment, is one of 19 that started in 2023, is one of 145 in phase 4, reaches primary completion later than 43 of the 64 other live ones, and was the 246th registered.

Pain, Postoperative

5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

53 of the 329 studies testing opioids in Pain, Postoperative are open now, in 12 countries. Recruiting first, the newest first:

48 more — sign in →

By country, each count listing its studies:

All 53 open studies →

About opioids

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 329 studies testing opioids in Pain, Postoperative, or all of them as a file.
02

Study summary

The investigators hypothesize that not prescribing opioids after uncomplicated, outpatient IHR will be non-inferior to prescribing opioids (5 tablets of Oxycodone, 5mg; or surgeon preference for intolerance) with respect to requests for opioid refills. Additionally, the investigators believe there will be no significant difference in postoperative readmission for pain quality of life at 30 days in either group.

Read the detailed description

Patients presenting with primary or recurrent inguinal hernias, previously repaired in an open fashion, will be considered eligible to be enrolled in this study. Exclusion criteria include patients who cannot tolerate general anesthesia, opioids or NSAIDS, surgeries requiring extensive dissection/hernia sac reduction, or additional procedures, patients requiring inpatient admission postoperatively, and patients who are not able to understand and sign a written consent form. Surgeons will notify a study coordinator at the end of surgery for randomization. Patients will be randomized to opioids versus no opioids at the end of surgery and stratified based on unilateral versus bilateral inguinal hernia repair. The intervention will be not prescribing opioids post-operatively. If patients require prescription for opioids after randomization for uncontrolled pain for the no opioid group, the patient will remain in the intervention group and will be treat as intention to treat which will be recorded in REDCap®. All patients in the study will receive prescriptions for Acetaminophen and Ibuprofen. No other intraoperative or postoperative differences will occur between the two groups.

Baseline information, operative details, and 30-day outcomes are already captured within the ACHQC database, allowing for follow-up, and data capture with decreased effort outside of routine care. Randomization data will be captured and stored in REDCap®.

Baseline patient demographics will be obtained at initial patient recruitment, and baseline ACHQC questionnaires will be completed following patient recruitment. All operative details are already routinely collected and stored in the ACHQC database. Patient-reported quality of life will also be assessed at baseline and at 30 days using the EuraHS Quality Of Life survey tool, which is collected for all patients entered into the ACHQC as part of the ACHQC Inguinal Hernia Postoperative Assessment. Patients will be required to complete these forms at each clinic visit, or via telephone contact, as this is standard procedure for all patients entered into the ACHQC. At the time of the one-month follow-up clinic visits, a routine physical examination will be performed on all patients.

Outcomes to be investigated:

  • Specific Aim #1: To determine if the use of post-operative use of opioids results in a difference in rate of opioid refills/requests when compared to those not initially prescribed opioids.
  • Specific Aim #2: To determine if the use of post-operative use of opioids results in a difference in Patient-Reported Outcome Measurement Information System (PROMIS Pain Intensity) scores at the 1 month follow up visit post-operatively when compared to those not prescribed opioids.
  • Specific Aim #3: To determine if the use of post-operative use of opioids results in a difference in EuraHS (European registry for abdominal wall hernias) Quality of Life (QoL) scores at the 1 month follow up visit post-operatively when compared to those not prescribed opioids.
  • Specific Aim #4: To determine if the use of post-operative use of opioids results in a difference in all 30-day complications when compared to those not prescribed opioids.
03

Conditions studied

  • Postoperative Pain
  • Inguinal Hernia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 years or older
  • Patients undergoing elective unilateral or bilateral inguinal hernia repairs
  • Patients able to tolerate general anesthesia

Exclusion criteria

Exclusion Criteria:

  • Patients who cannot tolerate general anesthesia,
  • Patients who cannot tolerate opioids or NSAIDS,
  • Patients on opioids for chronic pain management (defined as near daily use within 90 days),
  • Patients who undergo surgeries requiring extensive dissection/hernia sac reduction, or additional procedures,
  • Patients requiring inpatient admission postoperatively
  • Patients who are not able to understand and sign a written consent form
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
904 participants (estimated)

Study arms

  • Other
    Minimal Opioids

    Standard of care 5 tablets of Oxycodone (5mg) every 6 hours as needed for pain

    Drug: Opioids

  • Other
    No opioids

    Standard of care

    Other: No opioids

Interventions

  • Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)

    Also known as: Opioid

  • OtherNo opioids

    Standard of care, patients will not receive a prescription for opioids.

06

What researchers measure

Primary outcomes

  1. Opioid refills/requests

    The number of opioid prescription refills/requests will be compared between the two groups

    Time frame: At the one month follow up visit

Secondary outcomes

  1. Postoperative pain

    Postop pain will be assessed using the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Intensity 3a scale scale between the two groups where higher scores mean worse pain

    Time frame: At the one month follow up visit

  2. Quality of life, pain, cosmesis

    Quality of life, pain, and cosmetic outcomes will be assessed using the EuraHS (European registry for abdominal wall hernias) Quality of Life scale between the two groups where higher scores mean worse quality of life.

    Time frame: At the one month follow up visit

  3. Patient satisfaction

    Overall patient satisfaction: patients will be asked if they are dissatisfied, neutral, or satisfied with respect to their postoperative pain management and the responses will be compared between the two groups

    Time frame: At the one month follow up visit

  4. Number of emergency room (ER)/clinic/urgent care visits for pain

    The number of emergency room/clinic/urgent care visits for pain will be compared between the two groups

    Time frame: At the one month follow up visit

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2027, 47 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 47 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Jul 3, 2023
StartActual
Jul 10, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05929937
Lead sponsor
Clayton Petro
Responsible party
Clayton Petro (Assistant Professor of Surgery Lerner College of Medicine, The Cleveland Clinic) — Sponsor-investigator
First posted
Jul 3, 2023
Start date
Jul 10, 2023
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

Clayton C Petro, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opioids

Start the discussion